Evidence Review
Cancer Prevention
A 2022 systematic review by Kapała et al. examined 72 human and animal studies assessing lycopene's anti-cancer properties [1]. Approximately 70% of in vivo studies confirmed anti-cancer activity. Prostate cancer was the most-studied cancer type, with multiple mechanisms identified: regulation of oxidative and inflammatory processes, induction of apoptosis, inhibition of cell division, and suppression of angiogenesis and metastasis.
Holzapfel et al. (2013) reviewed both molecular mechanisms and clinical evidence specifically for prostate cancer [2]. The prostate concentrates lycopene at levels roughly 10-fold higher than serum, and men with higher prostate lycopene concentrations show lower rates of aggressive disease. Lycopene's effects operate partly through inhibition of IGF-1 receptor signaling, a pathway associated with prostate cancer proliferation. The review notes that while epidemiological associations are compelling, large well-designed randomized trials are still limited, meaning the evidence is suggestive rather than definitive.
A six-month intervention in 128 men with elevated PSA found that increased lycopene intake altered the serum metabolome in ways consistent with reduced prostate cancer risk, including lower pyruvate levels. A prospective cohort study in older adults at high cardiovascular risk (Mediterranean population) found higher lycopene intake was independently associated with lower prostate cancer incidence.
Strength of evidence for cancer: Moderate. Epidemiological data and mechanistic evidence are strong; RCT evidence remains limited.
Cardiovascular Health
Gajendragadkar et al. conducted a randomized double-blind trial with 36 statin-treated CVD patients and 36 healthy volunteers given either 7 mg lycopene or placebo daily for two months [3]. In CVD patients, endothelium-dependent vasodilatation improved by 53% (95% CI: +9% to +93%, P = 0.03 vs. placebo). Healthy volunteers showed no significant change, suggesting lycopene restores impaired endothelial function rather than enhancing normal function beyond its baseline.
A systematic review and meta-analysis by Cheng et al. (2017) pooled data from multiple trials on tomato and lycopene supplementation [4]. The analysis found significant reductions in LDL cholesterol, total cholesterol, and systolic blood pressure. LDL reduction averaged approximately 4.1 mg/dL across studies. The review noted considerable heterogeneity between trials, partly due to variation in lycopene dose, food matrix, and population characteristics.
Strength of evidence for cardiovascular: Moderate. RCTs show endothelial improvement in CVD populations; lipid effects are modest but consistent across studies.
Skin UV Protection
Grether-Beck et al. performed a double-blinded, placebo-controlled, crossover study in which participants received either lycopene or placebo, then were exposed to simulated UV radiation [5]. Lycopene supplementation significantly reduced expression of UVB/A and UVA1 marker genes — heme oxygenase-1, ICAM-1, and MMP-1 — all established indicators of UV-induced skin damage. MMP-1 suppression is particularly relevant because this enzyme degrades type I collagen and drives photoaging.
An earlier human study found that daily consumption of tomato paste containing 16 mg lycopene for 12 weeks resulted in 40% less UV-induced skin redness (erythema) compared to controls. Notably, natural (tomato-derived) lycopene outperformed synthetic lycopene in photoprotection trials, attributed to better bioavailability and co-extracted carotenoids including beta-carotene.
Strength of evidence for photoprotection: Moderate. Mechanistic and human experimental data are consistent; lycopene is not a sunscreen replacement but provides meaningful internal photoprotection at dietary doses.
Safety and Considerations
Lycopene is generally recognized as safe. Excessive intake of lycopene-rich foods can cause lycopenemia — orange-red skin discoloration — which is harmless and reversible. High-dose supplement use (above 30 mg/day) has not been associated with serious adverse effects in short-term trials. Those on blood-thinning medications should be aware that lycopene has mild antiplatelet effects.